



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 16/09/2011.

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL DESIGNS
FOR THE WEEK-ENDING OF 03/09/2011 TO BE PUBLISHED. IN
THE 19/09/2011 GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

29-08-2011

631/2011	Bayer CropScience AG, Germany (Priority 01-09-2010 Europe)	“N-(Tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides and their use as herbicides”
632/2011	Unilever PLC United Kingdom (Priority 12-10-2010 Europe)	“Process for manufacturing green tea”
633/2011	Boehringer Ingelheim International GmbH Germany (Priority 03-09-2010 Europe)	“Vegf-binding molecules”
634/2011	Portola Pharmaceuticals, Inc. USA Merck Sharp & Dohme Corp. USA (Priority 18-03-2011 USA)	“Methods and formulations of treating thrombosis with betrixaban and a p-glycoprotein inhibitor”
635/2011	Portola Pharmaceuticals, Inc. USA Merck Sharp & Dohme Corp. USA (Priority 18-03-2011 USA)	“Crystalline forms of a factor xa inhibitor”
636/2011	Sanofi France (Priority 31-08-2010 France)	“Peptide or peptide complex binding to alpha2 integrin and methods and uses involving the same”

30-08-2011

637/2011	Annikki GmbH Austria (Priority 02-09-2010 Austria)	“Preparation of lignin”
638/2011	Glaxo Group Limited Great Britain (Priority 02-09-2010 China)	“Novel compounds”

639/2011 Takeda Pharmaceutical Company “Heterocyclic compound and use thereof”
Limited,
Japan
(Priority 02-09-2010 Japan)

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

995/2003 F. Hoffmann-La Roche AG, "Antiviral Nucleoside Compound"
Switzerland

CO7H 19/06

141240

The present invention relates to nucleoside compound for the treatment of Hepatitis C viral infections including compound of formula I,



pharmaceutical composition comprising these compound

60/2007


Sanofi-Aventis
France

“Tricyclic n-eteroarylcarboxamide compound”

A61P 29/00, A61K 31/4188

141241

The invention relates to tricyclic N-heteroaryl-carboxamide compounds containing a benzimidazole unit, of formula (I)



in which A is, with the C-N bond of the benzimidazole unit with which it is fused, a 4- to 7-membered monocyclic heterocycle or monocyclic heteroaryl containing from one to three heteroatoms selected from O, S and N, including the nitrogen atom of the benzimidazole unit; P is an 8-, 9-, 10- or 11-membered bicyclic heterocycle or bicyclic heteroaryl containing from 1 to 6 heteroatoms selected from N, O and S; R₁ is from one to four atoms or groups, which may be identical or different; Y is an oxygen or sulphur atom; R₂ is a hydrogen atom, a halogen atom, or a C₁-C₅-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl-C₁-C₃-alkylene, C₁-C₆- fluoroalkyl or C₁-C₆-alkoxy group; R₃ is from one to three atoms or groups, which may be identical or different.

The invention also relates to a process for preparing the compounds and to the therapeutic application thereof.

203/2007

Banyu Pharmaceutical Co.,
Limited.


“Trans-5'-methoxy-3'-oxo-N-methyl-N-(2-piperidin-1-yl)ethyl)-spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide compound”

CO7D 491/107

141242

[Problem] To provide a substance having an activity of antagonizing the binding of histamine to histamine-H3 receptor, or having an activity of inhibiting the homeostatic activity of histamine-H3 receptor.

[Means for Solution] A compound of the following formula (I) is provided:



[wherein X, Y, Z and W each independently represent a methine group optionally having 1 or 2 substituents, or a nitrogen atom (provided that a case where all of X, Y, Z and W are an optionally-substituted methine group); A, B and D represent -C(0)-, etc.; Q represents a methine group or a nitrogen atom; R represents an optionally-substituted group of the following formula (II-1): (wherein R^7 and R^8 each independently represent a lower alkyl group, etc.)].

2008/1190 Banyu Pharmaceutical Co.,
Limited.


“Pharmaceutically acceptable salt of Trans-5'-
methoxy-3'-oxo-N-methyl-N-(2-piperidin-1-yl)thl)-
spiro[cyclohexane-1,1'-(3'H)-4'- azaisobenzofuran]-
4-carboxamide compound”

CO7D 491/107

141243

[Problem] To provide a substance having an activity of antagonizing the binding of histamine to histamine-H3 receptor, or having an activity of inhibiting the homeostatic activity of histamine-H3 receptor.

[Means of solution] A pharmaceutically acceptable salt of the compound of the following formula (I) is provided



[wherein X, Y, Z and W each independently represent a methine group optionally having 1 or 2 substituents, or a nitrogen atom (provided that a case where all of X, Y, Z and W are an optionally-substituted methine group); A, B and D represent - C (0)-, etc.; Q represents a methine group or a nitrogen atom; R represents an optionally-substituted group of the following formula (wherein R⁷ and R⁸ each independently represent a lower alkyl group, etc.)].


2008/1191 Sanofi-Aventis
France

“A pharmaceutically acceptable salt of a tricyclic n-heteroarylcarboxamide compound”

A61P 29/00, A61K 31/4188

141244

The invention relates to pharmaceutically acceptable salts, hydrates or solvates of the tricyclic N-heteroarylcarboxamide compounds containing a benzimidazole unit, of formula (I)



in which A is, with the C-N bond of the benzimidazole unit with which it is fused, a 4- to 7-membered monocyclic heterocycle or monocyclic heteroaryl containing from one to three heteroatoms selected from O, S and N, including the nitrogen atom of the benzimidazole unit; P is an 8-, 9-, 10- or 11-membered bicyclic heterocycle or bicyclic heteroaryl containing from 1 to 6 heteroatoms selected from N, O and S; R₁ is from one to four atoms or groups, which may be identical or different; Y is an oxygen or sulphur atom; R₂ is a hydrogen atom, a halogen atom, or a C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl-C₁-C₃-alkylene, C₁-C₆- fluoroalkyl or C₁-C₆-alkoxy group; R₃ is from one to three atoms or groups, which may be identical or different.

The invention also relates to a process for preparing the salts of the compounds and to the therapeutic application thereof.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
141042	Novartis AG, Switzerland.	1054/19999
141043	Aventis Pharma S.A., France.	743/2003
141044	Boehringer Ingelheim International GmbH Germany	1043/2005
141045	Novartis AG, Switzerland.	757/2006
141046	Aventis Pharma S.A., France.	1582/2006
141047	Bayer Cropscience AG., Germany.	1247/2008
141048	Boehringer Ingelheim International GmbH Germany.	301/2010
141049	Novartis AG, Switzerland.	226/1997
141050	Lubna Iqbal, Dr. Kauser Siddique, Dr. Yasar Saleem, Dr. Husan Afroz Rizvi, Dr. Mufti Asif Ullah, PCSIR, Karachi – Pakistan.	220/2005
141051	E. I. Du Pont De Nemours and Company, USA.	676/2005
141052	Lurgi Zimmer GmbH, Germany.	703/2005

141053	N. V. Organon, Netherlands.	431/2006
141054	Daiichi Pharmaceuticals Company Ltd., Japan.	439/2006
141055	N. V. Organon, Netherlands.	1601/2006
141056	Vestergaard Frandsen S.A., Switzerland.	600/2007
141057	Honda Motor Co. Limited, Japan.	702/2007
141058	Vestergaard Frandsen S.A., Switzerland.	127/2008
141059	Bil Care Limited, India.	163/2008
141060	Linda Muller, Switzerland.	307/2008
141061	Astra Zeneca AB, Sweden.	665/2008
141062	Vestergaard Frandsen S.A., Switzerland.	767/2008
141063	ENI S.p.A., Italy. Institute Francais Du Petrole, France.	1528/2008
141064	Commercialbank Mattersburg Im Burgenland Aktiengesellschaft, Austria.	235/2009
141065	Novartis AG, Switzerland.	717/2009
141066	Rijksuniversiteit Groningen, Netherlands.	832/2009
141067	Otsuka Pharmaceuticals Factory Inc., Japan.	80/2010

141068	Clariant International Ltd., Switzerland.	414/2010
141069	Astra Zeneca AB, Sweden.	963/2010

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>29-08-2011</u>			
1	15865	Plastic Cane (Class-03)	M/s. Rehan Can (Pvt.) Ltd
<u>30-08-2011</u>			
2	15866	Footwear (Class-10)	Bata Pakistan Limited

(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056